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ABSTRACT
Background: Debate between the Calorie Restriction (CR) and Low-Carbohydrate Diet (LCD) 
has been continued for several years. We have started LCD therapy for diabetic patients since 
1999, and experienced good response to control hyperglycemia. Recently the risk of post-
prandial hyperglycemia for cardiovascular events is reported, and the range of glucose level 
is focused. Morbus (M) value is proposed to be a good index to show the range of glucose 
fluctuation. Usefulness of LCD and usefulness of M-value were shown by combined analysis.
Methods: Twenty-six patients with Type 2 Diabetes Mellitus (T2DM), who admitted to the 
Takao Hospital, were the subjects. They were 12 males and 14 females, and their age ranged 
from 38 to 78 years old. A few patients were new patients, but mostly referred from other hos-
pitals to receive LCD treatment. All patients started from CR therapy with 60% carbohydrate 
for 2 days, and then carried out LCD dietary therapy with 12% carbohydrates for 10-12 days. 
On day 2 and 12, blood glucose level was measured at 7 points a day to see the fluctuation from 
morning to night. Blood and urinary samples were corrected on the same day to get ordinary 
biochemical data and metabolic marker.
Results: To know the effect of LCD on different level of HbA1c, the patients were grouped 
to low (L; 6.1±0.5%), middle (M; 7.9±0.4%) and high (H; 9.2±0.7%) by HbA1c value. The 
M-values after 2 day CR were 26.1 (L), 94.1 (M) and 343 (H), respectively. The LCD therapy 
decreased M-value to 10.4 (L), 18.8 (M) and 84.2 (H), respectively. The significant reduction 
of M-values was a reflection of the improved postprandial glucose level. LCD was effective 
even in the bad controlled diabetic patients. In addition to the decreased triacylglycerol and 24 
hr urinary C-peptide, uric acid increased in all patients.
Conclusion: Ten to 12 day-dietary therapy with LCD was quite effective to improve blood 
glucose profile. Patients with high HbA1c could be safely treated by LCD. Blood glucose im-
provement was well correlated to the M-value.
KEYWORDS: Low-carbohydrate diet (LCD); Mean amplitude of glycemic excursions (MAGE); 
Morbus value (M-value); Type 2 Diabetes Mellitus (T2DM).
ABBREVIATIONS: LCD: Low-Carbohydrate Diet; CR: Calorie Restriction; T2DM: Type 2 Dia-
betes Mellitus; MAGE: Mean Amplitude of Glycemic Excursions; M-value: Morbus value; 
HOMA-R: Homeostasis Model Assessment insulin Resistance; HOMA-β: Homeostasis Model 
Assessment Beta-cell function.
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INTRODUCTION
In both developed and developing countries, diabetes mellitus 
has explosively increased, and there has been a lot of ongoing 
discussion regarding calorie restriction (CR) and low-carbohy-
drate diet (LCD) for dietary treatment. LCD was originally de-
veloped by Bernstein, Atkins and others,1,2 and now it becomes a 
universal topic of discussion.3-8
 The Japanese Dietetic Association recommended tak-
ing 50-60 % carbohydrate, but our group treated DM patients 
by LCD with 12% carbohydrate since 1999, and experienced a 
good response and prognosis.9-13 LCD often accompanied with 
increase of ketone bodies as a toxic substance, but recent study 
found the physiological role of beta-hydroxybutyrate, especially 
in the normal delivery and very low carbohydrate treatment was 
effective to treat gestational diabetes.13 It caused a paradigm 
change to use LCD for the treatment of diabetes.
 Recently, postprandial hyperglycemia is reported to be 
a risk factor of cardiovascular events. Several evaluation meth-
ods, such as M-value and mean amplitude of glycemic excur-
sions (MAGE) have been proposed to estimate the risk.14-18 Ef-
ficacy of these indexes under the LCD dietary treatment needed 
to be analyzed. By combining these 2 streams, we have inves-
tigated blood glucose changes in diabetic patients under a con-
trolled meal of CR and LCD in the light of diabetic and M-value 
aspects. 
SUBJECTS AND METHODS
The subjects of the study were 26 T2DM patients who planned 
to receive LCD therapy for 2 weeks. They were 12 males and 14 
females, with an average age 62.6±8.6 years old, ranging from 
38 to 78 years old. A few patients were newly diagnosed with 
T2DM, but mostly transferred from other hospitals with a wish 
to be treated by LCD. Before beginning with LCD, they were in-
structed well about it. They received the same treatment protocol 
for endocrine and metabolic examination.
 The study began with providing a conditioning CR diet 
to the patients for 2 days. CR diet included carbohydrates 60%, 
protein 15%, and lipids 25% with 1400 kcal/day according to the 
standard dietary therapy of the Japan Diabetic Society. Whereas, 
the diet for LCD was composed of carbohydrates 12%, pro-
tein 24%, lipids 64% with 1400 kcal/day according to the LCD 
method.9,12 Total intake of calorie was adjusted properly by the 
size or weight of the patients.
The schedule and protocol during admission were as follows:
1. On admission, HbA1c and other biochemical data were col-
lected. In the early morning on day 2, several biomarkers such 
as lipids and daily profile of glucose were measured.
2. On day 2 and 3, urinary excretion of C-peptide for 24 hours 
was measured. The dietary energy of CR and LCD was ad-
justed to 1400 kcal in average. On day 3 CR was changed to 
LCD.
3. On day 12, the daily profile of blood glucose and biomarkers 
were measured.
4. The daily profiles of blood glucose on day 2 and 12 were ana-
lyzed with the following method.
Statistical Analysis
For statistical analysis, all 26 patients were classified into 3 
groups according to their HbA1c level on the admission; the low 
(L) group: less than 6.9%, middle (M) group: 7.0-8.4%, high (H) 
group: more than 8.5%.
 The average blood glucose was calculated by the mean 
amplitude of glycemic excursions (MAGE), M-value, and the 
data between CR and LCD were compared. 
 The calculation of M-value is performed as follows; 1) 
the optimal blood glucose is set at 0, as the standard, 2) the ex-
ample is 100 mg/dL, 3) the further the blood glucose value devi-
ates from the standard, the greater will be the point assigned. 
Practically M-value was calculated by the following formula:
 M-value (Morbus value) is a logarithmic transformation 
of the deviation of glycemia from an arbitrary assigned “ideal” 
glucose value, with an expression of both the mean glucose value 
and the effect of glucose swings.14,15,19 The formula is as follows: 
M=MBS+MW, where MW=(maximum blood glucose-minimum 
glucose)/20; MBS=the mean of MBSBS; MBSBS=individual M-
value for each blood glucose value calculated as (absolute value 
of [10×log(blood glucose value/120)]).19
 The standard range of M-value is <180, borderline is 
180-320 and abnormal is >320. Whereas, in the MBS value, the 
standard range is <5, borderline is 5-10 and abnormal is >10. It 
was reported that multiple sampling and a 7-point glycemic trial 
per day would yield similar results.16,20
 Data was represented as the mean±standard deviation 
when the data were normal distribution. Pearson’s correlation 
coefficients were calculated using the JMP (Version 8) statistical 
analysis software (JMP Japan Division of SAS Institute Japan 
Ltd., Minato-ku, Tokyo, Japan) and Microsoft Excel analytical 
tool.
 
 Intergroup comparisons were made using the Wilcoxon 
rank sum test or the Bonferroni multiple comparison (Lambert 
3
M-value= M W / 20      where M 10log
120
BS BS PG
N BS BS
∑
+ =
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method). A significance level of less than 5% obtained using a 
two-tailed test was considered to be statistically significant. 
Ethical Considerations
The present study was conducted in compliance with the ethi-
cal principles of the Declaration of Helsinki and Japan’s Act on 
the Protection of Personal Information along with the Ministe-
rial Ordinance on Good Clinical Practice (GCP) for Drug (Or-
dinance of Ministry of Health and Welfare No. 28 of March 
27, 1997). Informed consent was obtained from the patients 
concerning this trial. The study was registered in advance with 
UMIN #R000029006.
RESULTS
Anthropometric data of the patients
Subjects were divided into 3 groups according to the HbA1c val-
ue, and the data recorded by examining the subjects is shown in 
Table 1. Low (L), middle (M) and high (H) groups are composed 
of 9, 9, 8 patients, respectively, and their HbA1c values were 
6.1±0.5%, 7.9±0.4%, 9.3±0.8%. BMI and abdominal circumfer-
ence are slightly high in the H group.
Blood glucose under CR and LCD therapy
The daily blood glucose changes by 7 points have been shown 
according to the three groups for CR (day 2) and LCD (day 12) 
(Figure 1). 
 The average glucose levels improved by LCD therapy 
from 133±17 mg/dL to 114±22 mg/dL in L group, from 180±45 
mg/dL to145±28 mg/dL in M group, and from 262±51 mg/dL to 
194±26 mg/dL in H group (p<0.05 in all groups) (Figure 2). 
M-value in CR and LCD
The changes of the M-value of blood glucose from CR (day 2) 
to LCD (day 12) are shown in Figure 3. The median levels of M-
value at CR and LCD were: 7.1 and 7.2 in L group, 50.8 and 8.8 
Table 1: Data of the Subjects Classified in 3 Groups.
Low group Middle group High group
1. Anthropometry
Number 9 9 9
Male/female 5/4 4/5 3/5
Age (years, mean±SD) 57.2±11.1 64.7±11.2 63.7±5.7
Body mass index  (kg/m2) 23.3±2.3 24.4±3.7 25.6±4.1
Abdominal circumference (cm) 84.4± 7.2 85.7±9.0 89.8± 9.5
2. Data on admission
HbA1c (%)* 6.1±0.5 7.9±0.4 9.3±0.7
HOMA-R 3.3 (2.2-3.8) 2.7 (1.6-5.2) 2.7 (1.8-4.3)
HOMA-β  * 78.4 (60.6-83.1) 29.5 (12.5-60.1) 11.8 (9.1-25.1)
eGFR (mL/min) 91.8±23.5 86.1±30.7 104±31.3
Urinary Uric acid/cre 0.42±0.14 0.53±0.16 0.63±0.13
3. Data on day 2
Fasting glucose (mg/dL)* 109.0±27.3 155.4±35.7 210.7±52.9
Glucose-120 min (mg/dL)* 167.8±56.4 217.7±72.3 329.8±32.5
M-value* 26.1±34.7 94.1±11.2 343.0±192.0
Triglyceride (mg/dL) 106.0±68.6 131.6±75.5 163.7±84.4
Uric acid (mg/dL) 5.5±1.5 5.7±1.1 4.9±0.9
4. Data on day 12
Fasting glucose (mg/dL) 98.3±14.2 121.5±23.9 130.0±27.8
Glucose-120 min (mg/dL) 118.4±20.9 142.2±34.7 164.8±47.1
M-value* 10.4±7.9 18.8±28.4 84.2±52.7
Triglyceride (mg/dL) 70.0±28.8 83.3±15.6 125.0±38.2
Uric acid (mg/dL) 6.5±1.8 6.8±1.9 6.2±1.2
Elevation of UA (mg/dL) 0.55 (0.28-0.93) 0.95 (0.45-1.37) 1.15 (0.6-1.8)
Data are expressed as mean±SD. 
   : median [25-75 percentile], 
*: significant difference (p<0.05) each other among 3 groups.
×
×
×
×
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
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in M group, 273.2 and 85.3 in H group, respectively (Figure 3a). 
The actual changes of M-value in all individual patients were 
shown in Figure 3b.
Urinary C-Peptide in CR and LCD
Urinary C-peptide in 24 hours was measured on day 2 (CR) 
and on day 3 (LCD) (Figure 4a). The median values of urinary 
C-peptide by CR were: L: 94.0 mg/day, M: 61.0 mg/day, and 
H: 70.5 mg/day, respectively, and those by LCD was 65.5(L), 
47.5(M) and 46.5 mg/dL (H), respectively. By paired-T analyses, 
three groups showed a statistically significant decrease (p<0.05).
 The urinary C-Peptide excretion by CR (day 2) and 
by LCD (day 3) showed statistically positive correlation of 
(p<0.01).
TG and Uric Acid
The changes in triglyceride value from CR (day 2) to LCD (day 
12) are shown in Figure 4b. TG from day 2 to day 12, there was a 
statistically significant decrease, which was <0.05, <0.01, <0.01, 
Figure 1: Daily Profile of Blood Glucose on CR (day 2) and LCD (day 12). Figure 2: Average Blood Glucose in CR (day 2) and LCD (day 
12). Average Glucose Levels in 3 Groups Decreased with 
Statistically Significant Difference (p<0.05). Data are Repre-
sented by mean±SD.
Figure 3: The Changes of M-value on CR (day 2) and LCD (day 12). a) Changes in 3 Groups, 
Data are mean±SEM. b) Actual Data of M-value in 3 Groups.
L: Low; M: Middle; H: High group; CR: Calorie restriction; LCD: Low-carbohydrate diet.
L: Low group; M: Middle group, H: High group; CR: Calorie restriction;  LCD: Low-carbohydrate diet.
ba
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respectively. 
 Median levels of TG value are: L: 96 mg/dL and 61 mg/
dL, M: 97 mg/dL and 85.5 mg/dL, H: 182 mg/dL and 145 mg/
dL, respectively.
 The changes in uric acid value from CR (day 2) to 
LCD (day 12) are shown in Figure 4c. The median levels by CR 
were: 5.0 mg/dL (L group), 5.7 mg/dL (M group), and 4.6 mg/
dL (H group), respectively. It increased to 6.3 mg/dL in L group, 
6.8 mg/dL in M group, and 6.0 mg/dL in H group, respectively. 
These elevation was statistically significant (p<0.05) in all three 
groups.
 There is a significant correlation between increase of 
uric acid and HbA1c levels (Figure 5). 
Figure 4: Comparison of Biomarkers on CR and LCD in Three groups. a) Urinary C-peptide on CR (day2) and LCD (day 3). 
b) Triglyceride Values on CR (day 2) and LCD (day 12). c)  Uric Acid Values on CR (day 2) and LCD (day 12).
Figure 5: Correlation between the Increase of Uric Acid and HbA1c Level. Uric acid 
levels were measured on Day 2 (CR) and Day 12 (LCD). Significant Correlation were 
observed between Increase of Uric Acid and HbA1c.
L: Low group; M: Middle group, H: High group; CR: Calorie restriction;  LCD: Low-carbohydrate diet.
a b
c
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DISCUSSION
The clinical effects of LCD have been recognized by many case 
reports.1-3,7 In Japan, our group have led a role to develop LCD 
diet for obesity and diabetic patients by a lot of books and re-
ports.8-13 In this report, we investigated the clinical effects of 
LCD in relation with M-value.
 Even though the subjects of this study were very het-
erogeneous, all patients showed a good response to the short 
term LCD therapy. Individual response was well shown by the 
change of M-value. Two day conditioning with CR was useful 
to determine the will and safe introduction of very low carbo-
hydrate diet. Carbohydrate intake by CR was 210 g and that by 
LCR was 42 g. Definition of LCD has not yet made, but 40% 
carbohydrate is recommended by the American Diabetic As-
sociation. Our very low carbohydrate diet was effective on all 
stage of diabetes, and contributed to reduce the dose of drug 
administration in most patients.
 LCD improved many aspects, such as improvement 
of hyperglycemia, hyperinsulinemia, hyperlipidemia, etc. De-
creased urinary C-peptide suggested the suppression of insulin 
secretion per day up to three-fourth times, because the regres-
sion curve showed y=0.73x+7.8.
 Recently, a risk of post-prandial hyperglycemia for 
the cardiovascular events is recognized. Fasting glucose and/or 
HbA1c could not show the above risk. Several methods have 
been proposed, like MAGE15 and M-values.14 Initially, Schli-
chtkrull14 measured the blood glucose levels 20 times per day. 
However, multiple sampling and 7-point glycemic trial per day 
have yielded similar results.16,20
 In this study, M-values of the 3 groups were significant-
ly decreased by LCD therapy. M-value can be a clinically useful 
index for evaluating the glucose profile of diabetic patients.
 As for the glucose fluctuation, the following 5 mark-
ers would be valuable:16,21 1) The mean amplitude of glycemic 
excursions (MAGE), 2) standard deviation (SD), 3) the mean of 
the daily difference (MODD), which are calculated via continu-
ous glucose monitoring (CGM).22,23 4) M-value, which estimates 
both average and fluctuation of blood glucose, and 5) 7-point 
glycemic trial, which is prevalent in-patients admitted in the 
hospital.16,21-23 Markers 4) and 5) were applied in this report, that 
can be easily calculated using a free software Excel by internet.
 The continuous glucose monitoring (CGM) measure-
ment for 48 hours would be ideal,24,25 but the 7-times method 
would be simple and useful without invasion. Seven points are 
before and 2 hours after each meal and at night before sleep. Our 
average blood glucose data, classified into 3 groups according 
to HbA1c value, were compatible for the two reports. One is the 
comparison between HbA1c and average blood glucose values,26 
and the other is reporting the regression correlation, estimated 
average glucose (eAG) (mg/dL)=28.7×A1c-46.7.27 In the future, 
glucose variability may be considered more important, due to its 
influence on cognitive ability.28
 LCD lowered TG levels in only 10 days, which were 
consistent with previous reports of LCD.29 The uric acid level 
was significantly elevated by LCD, and the elevated degree was 
significantly correlated with HbA1c. From our clinical experi-
ence with the LCD diet in thousands of patients, the changes in 
uric acid levels ran the gamut from increase, stabilization and 
decrease. One of the causes for elevated uric acid levels would 
be the insufficiency of total calorie intake in addition to LCD. If 
the total calorie intake per day were increased to the proposed 
necessary energy level stated by the Ministry of Welfare and La-
bor, then uric acid levels could remain within the normal range.
 There are several reports indicating a significant corre-
lation between uric acid values and insulin resistance.30-32 As the 
influence of LCD for renal function has been in discussion,33,34 
the metabolism and changes of uric acid metabolism will be in-
volved in the effect of LCD. So far, any report concerning uric 
acid elevation and LCD could not be found. As such, the rela-
tionship between these two factors is a subject for future study.
CONCLUSION
Ten to 12 day- dietary therapy with LCD was quite effective to 
improve blood glucose profile. Patients with high HbA1c could 
be safely treated by LCD. Blood glucose improvement was well 
correlated to the M-value.
 LCD improved many aspects, such as improvement of 
hyperglycemia, hyperinsulinemia, hyperlipidemia, etc. The uric 
acid level was significantly elevated by LCD, and the elevated 
degree was significantly correlated with HbA1c. It needs further 
study whether LCD itself causes elevation of uric acid or insuf-
ficient calorie intake would be the cause.
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